NLS biotech-1

Nordic Nanovector and all shareholders of APIM Therapeutics have entered into a definitive merger agreement to combine the companies in an all-stock transaction. Subject to completion of the agreement, Nordic Nanovector will purchase shares in APIM, and become the parent entity of APIM. The agreement follows the review that Nordic Nanovector conducted, in conjunction with […]

Salipro Biotech has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target. The collaboration brings together Salipro Biotech’s expertise in developing stable antigens of GPCRs, ion channels and transporters via its platform with Sanofi’s discovery programs to identify biologics with the desired therapeutic […]

The company has opened an office in Boston to support its increasing US clinical development, partnering and fund-raising activities. The new office is at the CIC in Boston, Massachusetts which has been a home for great entrepreneurs leading fast-growing companies since 1999, describes the company. “Boston is at the heart of one of the world’s […]

Shanghai Henlius Biotech has received IND approval from China’s National Medical Products Administration for a Phase 2 clinical trial of AC101 in combination with anti-PD-1 monoclonal antibody HANSIZHUANG, HANQUYOU and chemotherapy as a 1st line treatment for HER2-positive locally advanced/metastatic gastric cancer patients. Alligator out-licensed AC101 (HLX22) to the South Korean company AbClon, Inc. in […]

The company has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the company’s iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. The agreement is the first to be executed as part of Elicera’s strategy of finding collaborators and licensing partners for […]

Mendus has announced an agreement to enable the technology transfer for manufacturing of the company’s lead development program DCP-001 with Minaris Regenerative Medicine. DCP-001 is currently being evaluated in the ADVANCE II Phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON Phase 1 clinical trial […]